Coagulation factor viia Disease Interactions

Serious arterial and venous thrombotic events have been reported with the use of coagulation factor VIIa. Patients at an increased risk of thromboembolic complications may include those with a history of coronary heart disease, liver disease, disseminated intravascular coagulation, post-operative immobilizations, elderly patients, and neonates. It is recommended to exercise caution when administering coagulation factor VIIa to patients at risk and the potential benefit of treatment should be weighed against the risk of these complications.

Hypersensitivity reactions, including anaphylaxis, can occur with coagulation factor VIIa. Patients with a known hypersensitivity to mouse, hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions. Discontinue infusion and administer appropriate treatment when hypersensitivity reactions occur.